ARTHD Projected Dividend Yield

Arch Therapeutics Inc ( OTCBB : ARTHD )

Arch Therapeutics is a biotechnology company marketing or developing a number of products based on its AC5® self-assembling technology platform. Co.'s product candidates are derived from its AC5 self-assembling peptide technology platform and are referred to as AC5®. These include AC5® Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include, for example, AC5-G™ for gastrointestinal endoscopic procedures and AC5-V® and AC5® Surgical Hemostat for hemostasis inside the body.

20 YEAR PERFORMANCE RESULTS